Zacks: Brokerages Anticipate Gilead Sciences, Inc. (NASDAQ:GILD) Will Post Earnings of $1.68 Per Share

Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post $1.68 earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have issued estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.81 and the lowest is $1.50. Gilead Sciences reported earnings per share of $1.44 in the same quarter last year, which suggests a positive year-over-year growth rate of 16.7%. The company is expected to issue its next quarterly earnings results on Monday, February 3rd.

According to Zacks, analysts expect that Gilead Sciences will report full-year earnings of $7.01 per share for the current financial year, with EPS estimates ranging from $6.83 to $7.15. For the next fiscal year, analysts expect that the business will report earnings of $7.01 per share, with EPS estimates ranging from $5.94 to $7.80. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.01. The business had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.84 EPS.

Several equities research analysts recently issued reports on GILD shares. Cantor Fitzgerald dropped their price target on Gilead Sciences from $88.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada raised Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price target on the stock in a research report on Monday, July 29th. Citigroup set a $78.00 price target on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Co set a $81.00 price target on Gilead Sciences and gave the company a “buy” rating in a research report on Friday, October 25th. Finally, Raymond James dropped their target price on Gilead Sciences from $85.00 to $81.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $78.87.

In other news, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 2,095 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $66.06, for a total value of $138,395.70. Following the completion of the transaction, the executive vice president now directly owns 17,826 shares of the company’s stock, valued at approximately $1,177,585.56. The disclosure for this sale can be found here. In the last three months, insiders sold 17,288 shares of company stock valued at $1,108,682. Company insiders own 0.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in GILD. Advisors Preferred LLC bought a new position in shares of Gilead Sciences in the second quarter worth $26,000. First Financial Corp IN grew its stake in shares of Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 401 shares in the last quarter. Legacy Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth $37,000. Venturi Wealth Management LLC bought a new position in shares of Gilead Sciences in the third quarter worth $40,000. Finally, Evolution Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter worth $46,000. 80.03% of the stock is owned by institutional investors.

NASDAQ GILD traded up $1.26 on Tuesday, reaching $65.07. The company had a trading volume of 6,773,400 shares, compared to its average volume of 6,297,733. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.96 and a quick ratio of 2.87. The firm has a market capitalization of $80.73 billion, a PE ratio of 10.58, a P/E/G ratio of 3.39 and a beta of 1.09. Gilead Sciences has a 1 year low of $60.32 and a 1 year high of $72.90. The firm has a 50-day moving average of $64.01 and a 200-day moving average of $65.29.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.87%. The ex-dividend date of this dividend is Thursday, December 12th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: What is a Real Estate Investment Trust (REIT)?

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.